Trial Profile

A Dose Escalation and Expansion Study of the Safety and Pharmacokinetics of XL102 as Single-Agent and Combination Therapy in Subjects With Inoperable Locally Advanced or Metastatic Solid Tumors

Status: Discontinued

Phase of Trial: Phase I

Latest Information Update: 18 May 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Abiraterone (Primary) ; Fulvestrant (Primary) ; Prednisone (Primary) ; XL 102 (Primary)
Indications Adenocarcinoma; Advanced breast cancer; Carcinoma; Fallopian tube cancer; Neuroendocrine carcinoma; Ovarian cancer; Peritoneal cancer; Prostate cancer; Solid tumours; Triple negative breast cancer
Focus Adverse reactions; First in man; Therapeutic Use
Acronyms QUARTZ-101
Sponsors Exelixis

Most Recent Events

13 May 2024 Status changed from active, no longer recruiting to discontinued due to business reasons.
05 Feb 2024 Status changed from recruiting to active, no longer recruiting.
05 Sep 2023 Planned number of patients changed from 298 to 373.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com